Table 2.
Antimicrobial susceptibility profiles of enterococcal isolates investigated
| Drug | E. faecalis, n = 72 | E. faecium, n = 05 | Others, n = 38 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| R (%) | I (%) | S (%) | R (%) | I (%) | S (%) | R (%) | I (%) | S (%) | |
| Erythromycin | 54 (72) | 07 (9.7) | 11 (15.3) | 04 (80) | 0 | 01 (20) | 07 (18.4) | 04 (10.5) | 11 (28.9) |
| Tetracycline | 50 (69.4) | 0 | 22 (30.6) | 03 (60) | 0 | 02 (40) | 05 (13.2) | 0 | 33 (86.8) |
| Ciprofloxacin | 07 (9.7) | 06 (8.3) | 59 (81.9) | 03 (60) | 01 (20) | 01 (20) | x | x | x |
| Moxifloxacin | 01 (0.14) | 0 | 71 (98.6) | 0 | 0 | 05 (100) | 04 (10.5) | 04 (10.5) | 30 (78.9) |
| Ampicillin | 01 (1.4) | 0 | 71 (98.6) | 0 | 0 | 05 (100) | 02 (5.3) | 0 | 36 (94.7) |
| Gentamicin-Syn | 02 (2.8) | 0 | 72 (100) | 0 | 0 | 05 (100) | 01 (2.6) | 0 | 01 (2.6) |
| Nitrofurantoin | 0 | 0 | 72 (100) | 01 (20) | 01 (20) | 03 (60) | 01 (2.6) | 03 (7.9) | 34 (89.5) |
| Vancomycin | 0 | 0 | 72 (100) | 0 | 0 | 05 (100) | 20 (52.6) | 0 | 18 (47.4) |
| Teicoplanin | 0 | 0 | 72 (100) | 0 | 0 | 05 (100) | 03 (7.9) | 0 | 35 (92.1) |
| Linezolid | 0 | 0 | 72 (100) | 0 | 0 | 05 (100) | 01 (2.6) | 04 (10.5) | 34 (89.5) |
| Daptomycin | 0 | 0 | 64 (88.9) | 0 | 0 | 01 (20) | 0 | 0 | 07 (18.4) |
| MDR | NA | NA | NA | NA | NA | NA | |||
| vanA | – | – | – | – | – | – | 06 (15.8) | – | – |
| vanB | – | – | – | – | – | – | 03 (7.9) | – | – |
S Susceptible, I Intermediate, R Resistant; −,Negative; x –MICs for these species (see “others”) are not reported by the Phoenix system
MDR, multidrug resistant (isolate resistant to three or more antibiotic classes)
“Others” denotes E. casseliflavus/gallinarum, E. raffinosus, E. hirae, E. durans, and the 10 isolates that were not identified to species level